ABSTRACT
Lung cancer is a major cause of cancer death among both genders in all around the world. Radiotherapy (RT) is an important component of the multidisciplinary approach to lung cancer treatment. Although computed tomography (CT)-based planning is the current minimum standard in lung cancer radiotherapy, in addition to the anatomical information provided by CT, thanks to the integration of fluorine-18 fluorodeoxyglucose (F-18 FDG)-labeled positron emission tomography/computed tomography (PET/CT) when transferred to RT, biological characteristics of the tumor also provide important information in treatment planning and tumor identification. The contributions of F-18 FDG PET/CT to lung cancer RT can be listed as follows: (i) It has an important role in accurate staging of the disease before the RT decision is made (ii) PET/CT provides invaluable information for the determination of tumor and involved lymph nodes in RT planning (iii) PET/CT allows dose-escalation in tumor tissue (iv) PET/CT has an important role in evaluating RT response and detecting residual/recurrent disease. In this review, the role of F18- FDG PET/CT in RT treatment planning is explained in accordance with current literature data.
Keywords:
Lung cancer, F-18 FDG PET/CT, non-small cell lung cancer, small cell lung cancer, radiotherapy planning
References
1
WHO. Available from: https://www3.paho.org/hq/index.php?option=com_docman&view=download&category_slug=4-cancer-country-profiles-2020&alias=51561-global-cancer-profile 2020&Itemid=270&lang=en. Accessed: February 2023.
2
Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 2021;4:e214708.
3
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019;94:1623-1640.
4
Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv1-iv21.
5
Le Pechoux C, Faivre-Finn C, Ramella S, et al. ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiother Oncol 2020;152:89-95.
6
Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume defnition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 2018;127:1-5.
7
Vaz SC, Adam JA, Delgado Bolton RC, et al. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. Eur J Nucl Med Mol Imaging 2022;49:1386-1406.
8
Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One 2016;11:e0146195.
9
Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol 2014;9:834-842.
10
Kubota K, Matsuno S, Morioka N, et al. Impact of FDG-PET fndings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer. Ann Nucl Med 2015;29:431-441.
11
van Tinteren H, Hoekstra OS, Smit EF, et al. Efectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-1393.
12
MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293.
13
Martucci F, Pascale M, Valli MC, et al. Impact of 18F-FDG PET/CT in staging patients with small cell lung cancer: a systematic review and meta-analysis. Front Med 2020;6:336.
14
Purdy JA. Current ICRU definitions of volumes: limitations and future directions. Semin Radiat Oncol 2004;14:27-40.
15
ICRU. Prescribing, Recording and Reporting Photon Beam Therapy. Report 50. Bethesda, MD: International Commission on Radiation Units and Measurements, 1999.
16
ICRU. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Report 62. Bethesda, MD: International Commission on Radiation Units and Measurements, 1999.
17
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-354.
18
Konert T, Vogel W, MacManus MP, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 2015;116:27-34.
19
van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in nonsmall-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007;68:771-778.
20
Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006;64:435-448.
21
Chi A, Nguyen NP. The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Front Oncol 2014;4:273.
22
Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86.
23
Berberoğlu K. Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer. Mol Imaging Radionucl Ther 2016;25:50-62.
24
Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDGPET). J Thorac Cardiovasc Surg 1995;110:130-139.
25
Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora’s box? Int Jradiat Oncol Biol Phys 2004;59:4-5.
26
Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 2005;46:1342-1348.
27
Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2012;82:1164-1171.
28
Greco C, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumour volume defnition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125-134.
29
Bradley J, Bae K, Choi N, et al. A phase II comparative study of gross tumor volume defnition with or without PET/CT fusion in dosimetric planning for nonsmall-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 2012;82:435-441.e1.
30
Hallqvist A, Alverbratt C, Strandell A, et al. Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: a systematic review and meta-analysis. Radiother Oncol 2017;123:71-77.
31
Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-324.
32
Steinfort DP, Siva S, Leong TL, et al. Systematic endobronchial ultrasound-guided mediastinal staging versus positron emission tomography for comprehensive mediastinal staging in NSCLC before radical radiotherapy of non-small cell lung cancer: a pilot study. Medicine (Baltimore) 2016;95:e2488.
33
Nestle U, Rischke HC, Eschmann SM, et al. Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process. Eur J Cancer 2015;51:2525-2533.
34
Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: stand - ard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 2020;38:706-714.
35
Lambin P, Petit SF, Aerts HJ, et al. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2009;2010:145-152.
36
Piperdi H, Portal D, Neibart SS, Yue NJ, Jabbour SK, Reyhan M. Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field. Front Oncol 2021;11:770382.
37
Kong FM, Ten Haken RK, Schipper M, et al. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2017;3:1358-1365.
38
Kong FM, HU C, Haken RT, et al. NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). Journal of Clinical Oncology 2021;39:(Suppl 15).
39
Lee E, Zeng J, Miyaoka RS, et al. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. Med Phys 2017;44:3418-3429.
40
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
41
Cliffe H, Patel C, Prestwich R, Scarsbrook A. Radiotherapy response evaluation using FDG PET-CT-established and emerging applications. Br J Radiol 2017;90:20160764.
42
Decazes P, Thureau S, Dubray B, Vera P. How to use PET/CT in the evaluation of response to radiotherapy. Q J Nucl Med Mol Imaging 2018;62:152-164.
43
Torun N. PET/CT in the Evaluation of Radiotherapy Response. Nucl Med Semin 2021;7:212-219.
44
Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? Nucl Med Mol Imaging 2018;52:5-15.
45
Machtay M, Duan F, Siegel BA, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 2013;31:3823-3830.
46
Markovina S, Duan F, Snyder BS, Siegel BA, Machtay M, Bradley JD. Regional Lymph Node Uptake of [(18)F] Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced NonSmall Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. Int J Radiat Oncol Biol Phys 2015;93:597-560.
47
Usmanij EA, de Geus-Oei LF, Troost EG, et al. 18F-FDG PET early response evaluation of locally advanced non–small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 2013;54:1528-1534.
48
NCCN Guidelines Version 2.2023. Non-Small Cell Lung Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf